Leveraging Real-world Evidence in a Rare Disease Oncology Drug Approval

August 14, 2020

Parexel experts discuss a recent project involving a Rare Disease Oncology therapeutic, in which our experts leveraged Real-world Evidence and FDA/Regulatory expertise to develop and execute a Synthetic Control Arm approach.

Previous Video
Leveraging Real-world Evidence in a Rare Disease Oncology Drug Approval
Leveraging Real-world Evidence in a Rare Disease Oncology Drug Approval

Parexel experts discuss a recent project involving a Rare Disease Oncology therapeutic, in which our expert...

Next Video
Leveraging Real-World Evidence in a Rare Disease Oncology Drug Approval
Leveraging Real-World Evidence in a Rare Disease Oncology Drug Approval

Parexel experts discuss a recent project involving a Rare Disease Oncology therapeutic, in which our expert...